FDA official logo
GSRS logo
PFDA official logo

RANIBIZUMAB

  • UNII: ZL1R02VT79
  • Preferred Substance Name: RANIBIZUMAB

  • 347396-82-1
  • BYOOVIZ
  • CIMERLI
  • FAB-12 VARIANT Y0317
  • FYB201
  • FYB-201
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR) FAB FRAGMENT (HUMAN-MOUSE MONOCLONAL RHUFAB V2 1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL RHUFAB V2 LIGHT CHAIN
  • PF582
  • PF-582
  • PF-582 (RANIBIZUMAB BIOSIMILAR)
  • RANIBIZUMAB [EMA EPAR]
  • RANIBIZUMAB [INN]
  • RANIBIZUMAB [JAN]
  • RANIBIZUMAB [MART.]
  • RANIBIZUMAB [MI]
  • RANIBIZUMAB [PURPLE BOOK CDER]
  • RANIBIZUMAB [USAN]
  • RANIBIZUMAB [VANDF]
  • RANIBIZUMAB [WHO-DD]
  • RANIBIZUMAB BIOSIMILAR PF582
  • RANIBIZUMAB NUNA [WHO-DD]
  • RANIBIZUMAB-EQRN
  • RANIBIZUMAB-NUNA
  • RBZ
  • RG-3645
  • RHUFAB
  • SUSVIMO

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo